ZA200409331B - Method of treating diabetes - Google Patents

Method of treating diabetes

Info

Publication number
ZA200409331B
ZA200409331B ZA2004/09331A ZA200409331A ZA200409331B ZA 200409331 B ZA200409331 B ZA 200409331B ZA 2004/09331 A ZA2004/09331 A ZA 2004/09331A ZA 200409331 A ZA200409331 A ZA 200409331A ZA 200409331 B ZA200409331 B ZA 200409331B
Authority
ZA
South Africa
Prior art keywords
treating diabetes
diabetes
treating
Prior art date
Application number
ZA2004/09331A
Other languages
English (en)
Inventor
A Wolff Andrew
Markus Jerling
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of ZA200409331B publication Critical patent/ZA200409331B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA2004/09331A 2002-05-21 2004-11-19 Method of treating diabetes ZA200409331B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38278102P 2002-05-21 2002-05-21
US45933203P 2003-03-31 2003-03-31
PCT/US2003/016277 WO2003099281A2 (en) 2002-05-21 2003-05-21 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes

Publications (1)

Publication Number Publication Date
ZA200409331B true ZA200409331B (en) 2005-06-29

Family

ID=29586970

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2004/09331A ZA200409331B (en) 2002-05-21 2004-11-19 Method of treating diabetes

Country Status (16)

Country Link
US (4) US20040063717A1 (enExample)
EP (2) EP1505977B1 (enExample)
JP (1) JP4546824B2 (enExample)
KR (1) KR101030943B1 (enExample)
CN (1) CN100551370C (enExample)
AU (1) AU2003248558B8 (enExample)
BR (1) BR0311161A (enExample)
CA (1) CA2486712C (enExample)
ES (1) ES2523873T3 (enExample)
IL (4) IL165304A0 (enExample)
MX (1) MXPA04011530A (enExample)
NO (1) NO330336B1 (enExample)
NZ (1) NZ536678A (enExample)
RU (1) RU2320343C2 (enExample)
WO (1) WO2003099281A2 (enExample)
ZA (1) ZA200409331B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
NZ536678A (en) 2002-05-21 2007-01-26 Cv Therapeutics Inc Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
BRPI0606403A2 (pt) * 2005-01-06 2009-06-23 Cv Therapeutics Inc formulações farmacêuticas com liberação sustentada e seus usos
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678272A1 (en) 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
MX2009010895A (es) * 2007-04-12 2009-10-26 Cv Therapeutics Inc Ranolazina para aumentar la secrecion de insulina.
BRPI0721741A2 (pt) * 2007-05-31 2013-02-13 Cv Therapeutics Inc mÉtodo de tratamento de diabetes
WO2008150565A2 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
EA201070914A1 (ru) * 2008-02-06 2011-04-29 Гайлид Сайэнсиз, Инк. Применение ранолазина для лечения боли
US20110280941A1 (en) * 2008-12-11 2011-11-17 Mefford Scientific, Llc Compositions of proton pump inhibitors and insulin secretagogues, and methods of their use to treat diabetes
AU2010248948A1 (en) * 2009-05-14 2011-12-01 Gilead Sciences, Inc. Ranolazine for the treatment of CNS disorders
JO3183B1 (ar) * 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
CN110812344A (zh) * 2019-12-17 2020-02-21 卓和药业集团有限公司 一种治疗糖尿病合并心绞痛的药物组合物及制备方法
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
EP0283168A3 (en) * 1987-03-16 1989-06-14 American Home Products Corporation Fluorooxirane carboxylates
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DK0407780T3 (da) 1989-06-23 1996-09-30 Syntex Inc Ranolazin og beslægtede piperaziner til anvendelse i behandling af væv, der har været udsat for fysisk eller kemisk skade
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
CA2339088A1 (en) * 1998-08-11 2000-02-24 The Governors Of The University Of Alberta Compositions and methods for identifying mammalian malonyl coa decarboxylase inhibitors, agonists and antagonists
US6479496B1 (en) 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US20050245502A1 (en) 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
US6528511B2 (en) 2000-02-18 2003-03-04 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
FR2805463B1 (fr) * 2000-02-25 2003-01-24 Adir UTILISATION DE LA TRIMETAZIDINE POUR L'OBTENTION DE COMPOSITIONS PHARMACEUTIQUES DESTINEES A INHIBER L'ACYL-CoA ACETYLTRANSFERASE
US20030220312A1 (en) 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
CN1462191B (zh) 2000-05-19 2013-07-24 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
CA2415826A1 (en) 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
CA2434436A1 (en) 2001-01-26 2002-08-01 Teddy Kosoglou Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
ATE292633T1 (de) * 2001-07-19 2005-04-15 Cv Therapeutics Inc Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitoren
US20030220310A1 (en) 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20050250676A1 (en) 2001-11-19 2005-11-10 Aventis Pharma Deutschland Gmbh Method of activating insulin receptor substrate-2 to stimulate insulin production
US6958352B2 (en) 2002-02-08 2005-10-25 Smithkline Beecham Corporation Compounds for inhibiting insulin secretion and methods related thereto
US20030220344A1 (en) 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
NZ536678A (en) 2002-05-21 2007-01-26 Cv Therapeutics Inc Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
AU2004217441A1 (en) 2003-03-05 2004-09-16 Metabolex Inc. Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-TRP
EP2377528B1 (en) 2003-06-12 2014-02-19 The Board of Regents of the University of Colorado Fatty acid metabolism inhibitors for use in the treatment of cancer
US7060723B2 (en) 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
WO2005115379A2 (en) 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2006053161A1 (en) 2004-11-09 2006-05-18 Cv Therapeutics, Inc. Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
BRPI0606403A2 (pt) 2005-01-06 2009-06-23 Cv Therapeutics Inc formulações farmacêuticas com liberação sustentada e seus usos
AU2006223212A1 (en) 2005-03-11 2006-09-21 Hong Kong Nitric Oxide Limited Combination therapy for endothelial dysfunction, angina and diabetes
JP2010514696A (ja) 2006-12-21 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心血管症状の低減
US20080248112A1 (en) 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
CA2678272A1 (en) 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090312340A1 (en) 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080193530A1 (en) 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
US20080233191A1 (en) 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
BRPI0721741A2 (pt) 2007-05-31 2013-02-13 Cv Therapeutics Inc mÉtodo de tratamento de diabetes
WO2008150565A2 (en) 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Ranolazine for elevated brain-type natriuretic peptide
EA201070914A1 (ru) 2008-02-06 2011-04-29 Гайлид Сайэнсиз, Инк. Применение ранолазина для лечения боли
US20100056536A1 (en) 2008-09-04 2010-03-04 Charles Antzelevitch Method of treating atrial fibrillation
US20100130436A1 (en) 2008-11-25 2010-05-27 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides
AU2010248948A1 (en) 2009-05-14 2011-12-01 Gilead Sciences, Inc. Ranolazine for the treatment of CNS disorders
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension

Also Published As

Publication number Publication date
MXPA04011530A (es) 2005-08-15
CA2486712C (en) 2012-01-03
US20040063717A1 (en) 2004-04-01
EP1505977A2 (en) 2005-02-16
US8314104B2 (en) 2012-11-20
EP1505977B1 (en) 2014-09-10
IL165304A0 (en) 2006-01-15
US20100197701A1 (en) 2010-08-05
IL213806A0 (en) 2011-07-31
IL213809A0 (en) 2011-07-31
WO2003099281A2 (en) 2003-12-04
US20140378465A1 (en) 2014-12-25
IL165304A (en) 2011-08-31
KR101030943B1 (ko) 2011-04-28
BR0311161A (pt) 2005-03-29
RU2320343C2 (ru) 2008-03-27
CA2486712A1 (en) 2003-12-04
HK1073441A1 (en) 2005-10-07
EP2332540A1 (en) 2011-06-15
JP2005532331A (ja) 2005-10-27
RU2004133670A (ru) 2005-06-10
AU2003248558B8 (en) 2009-07-09
CN100551370C (zh) 2009-10-21
NZ536678A (en) 2007-01-26
US20130102555A1 (en) 2013-04-25
NO330336B1 (no) 2011-03-28
AU2003248558B2 (en) 2009-03-12
ES2523873T3 (es) 2014-12-02
WO2003099281A3 (en) 2004-04-01
CN1652788A (zh) 2005-08-10
KR20040111677A (ko) 2004-12-31
JP4546824B2 (ja) 2010-09-22
NO20045554L (no) 2004-12-20
AU2003248558A1 (en) 2003-12-12
US8883750B2 (en) 2014-11-11

Similar Documents

Publication Publication Date Title
IL218909A0 (en) Treatment of diabetes
ZA200409331B (en) Method of treating diabetes
AU2003226301A8 (en) Method of treating cancer
AU2003283958A8 (en) Method of treating tremors
AU2003256847A8 (en) Method of treating cancer
EP1577280A4 (en) DEUTERATION PROCESS
IL165242A0 (en) Treatment for diabetes
IL166600A0 (en) Method of treating osteoarthritis
GB0302572D0 (en) Method of treatment
ZA200406910B (en) Method of treating mucus hypersecretion
GB0306309D0 (en) Method of treatment
EP1493716A4 (en) METHOD OF WASTE WATER TREATMENT
ZA200303274B (en) Method of treating shellfish.
IL154293A0 (en) Process of treating dates
PL376350A1 (en) Sludge treatment method
AU2003252188A8 (en) Method of ore treatment
GB0208897D0 (en) New method of treatment
AU2003299652A8 (en) Methods for treating diabetes
AU2002951913A0 (en) Method of treatment
GB0217493D0 (en) Novel methods of treatment
GB0221712D0 (en) Methods of treatment
AU2003236232A1 (en) Method for treatment of textile
AU2003209534A8 (en) The method of treating tuberculosis
GB0213198D0 (en) Method of treatment
GB0207091D0 (en) Method of treatment